Catheter Precision, Inc.
VTAKAMEXHealthcare● Active
$1.02
$-0.01(-0.97%)
Market Cap$1102083
P/E Ratio—
52W High$15.77
52W Low$0.75
Catheter Precision, Inc. (VTAK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VTAK · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 18, 2026EPS Actual
-$1.39
Est. -$20.90 · +93.3%
Revenue
$0.00B
Est. $0.00B · -73.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 18, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 4-Quarter EPS Beat Streak
VTAK reports quarterly as a AMEX-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | -$19.00 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 18, 2026 | -$20.90 | -$1.39 | +93.3% | $0.00B | $0.00B | -73.0% |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$20.90 | $1.53 | +107.3% | $0.00B | $0.00B | -86.0% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$26.60 | -$1.70 | +93.6% | $0.00B | $0.00B | -81.2% |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$34.20 | -$7.22 | +78.9% | $0.00B | $0.00B | -64.7% |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.20 | -$0.36 | -80.0% | $0.00B | $0.00B | -52.3% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.20 | -$0.70 | -251.5% | $0.00B | $0.00B | -46.8% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$1.80 | -$2.01 | -11.7% | $0.00B | $0.00B | -65.7% |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
-$19.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 18, 2026Beat
EPS Actual
-$1.39
EPS Est.
-$20.90
EPS Surpr.
+93.3%
Revenue
$0.00B
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
$1.53
EPS Est.
-$20.90
EPS Surpr.
+107.3%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$1.70
EPS Est.
-$26.60
EPS Surpr.
+93.6%
Revenue
$0.00B
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$7.22
EPS Est.
-$34.20
EPS Surpr.
+78.9%
Revenue
$0.00B
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.20
EPS Surpr.
-80.0%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.70
EPS Est.
-$0.20
EPS Surpr.
-251.5%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$2.01
EPS Est.
-$1.80
EPS Surpr.
-11.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-5.70 | $-5.70 | $-5.70 | 1 |
| Q3 FY2026 | $-13.30 | $-13.30 | $-13.30 | 1 |
| Q2 FY2026 | $-19.00 | $-19.00 | $-19.00 | 1 |
| Q1 FY2026 | $-20.90 | $-20.90 | $-20.90 | 1 |
| Q4 FY2025 | $-20.90 | $-20.90 | $-20.90 | 1 |
| Q3 FY2025 | $-26.60 | $-26.60 | $-26.60 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 18, 2026 | +93.3% | $0.76 | $0.83 | +9.07% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +107.3% | $1.05 | $1.01 | -3.81% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +93.6% | $2.31 | $2.05 | -11.26% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +78.9% | $3.62 | $3.37 | -6.91% |
| ▼ Q2 FY2025 | May 14, 2025 | -80.0% | $5.83 | $5.66 | -2.92% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -251.5% | $6.74 | $6.54 | -2.97% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -11.7% | $8.26 | $9.12 | +10.41% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -111.8% | $29.64 | $30.21 | +1.92% |
Q2 FY2026+9.07%
Report Date
May 18, 2026
EPS Beat/Miss
+93.3%
Price Before
$0.76
Price After
$0.83
Q1 FY2026-3.81%
Report Date
Mar 31, 2026
EPS Beat/Miss
+107.3%
Price Before
$1.05
Price After
$1.01
Q4 FY2025-11.26%
Report Date
Nov 13, 2025
EPS Beat/Miss
+93.6%
Price Before
$2.31
Price After
$2.05
Q3 FY2025-6.91%
Report Date
Aug 11, 2025
EPS Beat/Miss
+78.9%
Price Before
$3.62
Price After
$3.37
Q2 FY2025-2.92%
Report Date
May 14, 2025
EPS Beat/Miss
-80.0%
Price Before
$5.83
Price After
$5.66
Q1 FY2025-2.97%
Report Date
Mar 31, 2025
EPS Beat/Miss
-251.5%
Price Before
$6.74
Price After
$6.54
Q4 FY2024+10.41%
Report Date
Nov 13, 2024
EPS Beat/Miss
-11.7%
Price Before
$8.26
Price After
$9.12
Q3 FY2024+1.92%
Report Date
Aug 14, 2024
EPS Beat/Miss
-111.8%
Price Before
$29.64
Price After
$30.21
Avg Beat Reaction-3.23%
Avg Miss Reaction+1.61%
Beat Rate4 / 8 quarters
Largest Move-11.26% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VTAK ends December
Catheter Precision, Inc. (VTAK) most recently reported earnings on May 18, 2026 for Q2 FY2026, posting EPS of $-1.39 — beating the analyst consensus of $-20.90 by +93.3%. VTAK has beaten EPS estimates for 4 consecutive quarters. The next VTAK earnings date is expected around September 1, 2026.
Each quarter, investors track VTAK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VTAK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VTAK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VTAK earnings · 5 questionsCatheter Precision, Inc.'s next earnings report is expected around September 1, 2026. VTAK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VTAK historically reports after market close (AMC).
VTAK earnings datewhen is VTAK earningsVTAK next earnings datewhen does VTAK report earningsVTAK earnings calendar
▸ Source: FMP · Catheter Precision, Inc. SEC filings · US GAAP · Catheter Precision, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026